Phosphagenics soars on Phase I oxymorphone patch results
This article was originally published in Scrip
It may have been only a small Phase I trial, but investors in Phosphagenics were sufficiently convinced by positive results with a new transdermal formulation of oxymorphone to send shares in the Australian drug delivery venture surging by nearly 50% on 24 October.
You may also be interested in...
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.